Structure Therapeutics, Inc. Earnings

Structure Therapeutics, Inc.’s revenue fell -100% since last year same period to $0Mn in the Q4 2024. On a quarterly growth basis, Structure Therapeutics, Inc. has generated NaN% jump in its revenue since last 3-months.

Structure Therapeutics, Inc.’s net profit fell -47.86% since last year same period to $-36.48Mn in the Q4 2024. On a quarterly growth basis, Structure Therapeutics, Inc. has generated -7.36% fall in its net profits since last 3-months.

Structure Therapeutics, Inc.’s net profit margin fell -Inf% since last year same period to -Inf% in the Q4 2024. On a quarterly growth basis, Structure Therapeutics, Inc. has generated NaN% jump in its net profit margins since last 3-months.

Structure Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.17 - a 10.93% jump from last quarter’s estimates.

Structure Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.17.

Structure Therapeutics, Inc.’s earning per share (EPS) jumped 58.62% since last year same period to -0.22 in the Q4 2024. This indicates that the Structure Therapeutics, Inc. has generated 58.62% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Structure Therapeutics, Inc.’s return on assets (ROA) stands at -0.14.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Structure Therapeutics, Inc.’s return on equity (ROE) stands at -0.19.